NCT01337505 2022-02-10
Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
Clinical Trials
4 trialsNCT01673438 2022-02-10
Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT01706835 2022-02-10
Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed
NCT02235688 2022-02-10
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Completed